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Objective: To compare the toxicity of image-guided
intensity-modulated radiotherapy (IG-IMRT) to the pelvis
or prostate bed (PB) only. To test the hypothesis that the
potentially injurious effect of pelvic irradiation can be
counterbalanced by reduced irradiated normal tissue
volume using IG-IMRT.
Methods: Between February 2010 and February 2012,
208 patients with prostate cancer were treated with
adjuvant or salvage IG-IMRT to the PB (102 patients,
Group PB) or the pelvis and prostate bed (P)
(106 patients, Group P). The Radiation Therapy Oncology
Group/European Organization for Research and Treat-
ment of Cancer criteria were used to evaluate toxicity.
Results: Median follow-up was 27 months. Toxicity G$2
in Group PB: in the bowel acute and late toxicities were
11.8% and 10%, respectively; urinary acute and late
toxicities were 10.8% and 15%, respectively. Toxicity G$2
in Group P: in the bowel acute and late toxicities were
both 13.2%; urinary acute and late toxicities were 13.2%
and 15.1%, respectively. No statistical difference in acute
or late toxicity between the groups was found (bowel:
p50.23 and p50.89 for acute and late toxicity, re-
spectively; urinary: p50.39 and p50.66 for acute and
late toxicity, respectively). Of the clinical variables, only
previous abdominal surgery was correlated with acute
bowel toxicity. Dosimetric parameters that correlated
with bowel toxicity were identified.
Conclusion: The toxicity rates were low and similar in
both groups, suggesting that IG-IMRT allows for a safe
post-operative irradiation of larger volumes. Further
investigation is warranted to exclude bias owing to non-
randomized character of the study.
Advances in knowledge: Our report shows that modern
radiotherapy technology and careful planning allow main-
taining the toxicity of pelvic lymph node treatment at the
acceptable level, as it is in the case of PB radiotherapy.
INTRODUCTION
The role of adjuvant post-prostatectomy irradiation in
prostate cancer has been recently established in three large
randomized trials.1–4 Adjuvant post-operative radiother-
apy should be offered to patients with adverse pathologic
ﬁndings at prostatectomy (i.e. seminal vesicle invasion,
positive surgical margins and extraprostatic extension),
while salvage radiotherapy should be proposed to patients
with a prostatic-speciﬁc antigen or local recurrence after
prostatectomy (with no adjuvant irradiation), in whom
there is no evidence of distant metastatic disease.1–4
Recent research also suggests the beneﬁt of post-operative
pelvic irradiation in patients with positive lymph
nodes.5–7 While the radiotherapy volume in patients with
pN1 will always include the pelvic lymph node area, the
optimal volume [prostate bed (PB) only or pelvis and
prostate bed (P)] in case of adjuvant or salvage irradiation
in pN0 or pNx has not been established.1 The ongoing
Radiation Therapy Oncology Group (RTOG) 0534 trial
will help in clarifying this issue, at least for salvage ther-
apy. The potential beneﬁt, i.e. improvement of tumour
control by inclusion of regional lymph node areas, should
exceed the risk of increased normal tissue injury with larger
irradiated volumes.
With the advent of new high-precision radiotherapy technolo-
gies such as image-guided radiotherapy or intensity-modulated
radiotherapy (IMRT), the irradiated volume of the normal tissue
might be reduced and, in consequence, the treatment toxicity
can be kept at an acceptable level. Although no randomized
controlled trial of IMRT vs three-dimensional conformal ra-
diotherapy (3DCRT) in prostate cancer is available, at least 13
non-randomized studies comparing IMRT with 3DCRT were
found.8 These comparative series showed that IMRT reduces late
rectal toxicity in patients with prostate cancer, allowing safe dose
escalation.8–11 However, the ﬁndings in favour of IMRT over
3DCRT regard the radical treatment of localized prostate cancer
where doses .70Gy are required.12 There are insufﬁcient data
comparing IMRTwith 3DCRT in the post-operative setting.12 In
daily practice, decision-making for patients referred for post-
prostatectomy irradiation is based on the assessed risk of pelvic
lymph node involvement, risk of normal tissue injury and
available technology.
In our department, since the installation of RapidArc® (Varian
Medical Systems, Palo Alto, CA) in February 2010, IMRT is
routinely proposed for patients with prostate cancer. In case of
post-prostatectomy irradiation, the decision regarding treatment
volume (PB vs P) is based on physician judgment, according to
general institutional guidelines.
The aim of this study was to retrospectively compare the toxicity
of pelvic image-guided intensity-modulated radiotherapy (IG-
IMRT) with PB IG-IMRT. Namely, our intent was to test the
hypothesis that the potentially injurious effect of pelvic irradi-
ation can be counterbalanced by reduced irradiated normal
tissue volume using IG-IMRT.
METHODS AND MATERIALS
Inclusion criteria
The inclusion criteria for this retrospective study were as fol-
lows: (1) patients referred for post-operative (adjuvant or sal-
vage) irradiation after surgery for prostate cancer between
February 2010 and February 2012; and (2) written informed
consent for radiotherapy. The study was notiﬁed to the Ethical
Committee of the European Institute of Oncology (IEO), Milan,
Italy (notiﬁcation regarding the clinical and dosimetric aspects
of image-guided radiotherapy for the prostate, IEO N79).
Surgery and radiotherapy
Surgery consisted of an open or robot-assisted laparoscopic
retropubic approach including radical prostatectomy with or
without pelvic lymph node dissection. In all cases, the indication
for irradiation was established within a multidisciplinary tu-
mour board.
Institutional guidelines for simulation CT and contouring were
employed.13 The planning 3-mm-slice CT scan (High Speed, GE
Healthcare) was acquired with patients in supine position using
a leg immobilization device (Combiﬁx™, CIVCO, Kalona, IA).
Patients were asked to have an empty rectum and full bladder for
the planning CT and for each treatment session, in order to
minimize daily variations in PB location.
PB and pelvic lymph node clinical target volumes (CTVs) were
contoured according to the guidelines of the European Orga-
nization for Research and Treatment of Cancer and RTOG.14–16
The presacral area was not included. Pelvic volume was added in
case of pN1 or cN0/pNx, if the estimated risk of lymph node
involvement was .30%, with the calculation based on available
Memorial Sloan Kettering Cancer Centre nomogram.17 In case
of pN1 disease, two nodal CTVs were contoured, namely neg-
ative and positive lymph node areas, respectively.
The margin between CTV and planning target volume was
5mm. Dose–volume histograms (DVHs) were computed. In-
stitutional DVH constraint guidelines have been established
based on our own data and the Quantitative Analysis of Normal
Tissue Effects in the Clinic Recommendation.18,19 For the
peritoneal cavity, we recommended that the dose of 45 Gy be
given to ,195 cm23 of the delineated volume. All patients were
treated with IG-IMRT using volumetric-modulated arc therapy
technologies (RapidArc). The plans were created using an
Eclipse™ treatment planning system v. 8.6.0 AAA (Varian, UT)
with 6-MV photon beams and a maximum dose rate of 600
MU/min. The Varian Trilogy® System equipped with a Millen-
ium multileaf collimator with 120 leaves (Varian Medical Sys-
tem, Palo Alto, CA) was employed for treatment delivery.
The prescribed dose depended on the radiotherapy intent (ad-
juvant or salvage in case of detectable PSA) and followed the
International Commission on Radiation Units and Measure-
ments 83 recommendations.20 The dose prescribed to the PB
was 66 or 69Gy in 30 fractions for adjuvant and salvage irra-
diation (2.2–2.3Gy/fraction, 5 fractions/week), respectively.
Pelvic doses were 51Gy and 54Gy in 30 fractions (1.7–1.8 Gy/
fraction) to the negative and positive lymph nodes areas, re-
spectively. In patients with more than one planning target vol-
ume, simultaneous integrated boost technique was employed.
The institutional target-positioning guidelines based on the
cone-beam CTmanual soft-tissue registration were followed. All
patients were imaged for the ﬁrst 3 fractions and weekly
thereafter. A preliminary match between the cone-beam CT data
set and planning CT scans was obtained by automatic image
registration and then manually reﬁned by a radiation oncologist
for improved target alignment (manual soft-tissue registration).
Detected misalignments were corrected by couch motion. In
case of unacceptable misalignment in the patient setup or var-
iation in hollow organ ﬁlling, the patient was repositioned and/
or corrective measures (such as ﬁlling or emptying of the rectum
and bladder) were undertaken in order to reproduce the plan-
ning situation as much as possible.
During radiotherapy, the patients were seen by a radiation on-
cologist once a week (no preventive measures were given before
radiotherapy and only symptomatic therapy was prescribed
when side effects occurred). After the treatment, the patients
were seen by a radiation oncologist or urologist every 6–9months,
or more frequently if clinically indicated.
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Table 1. Patient, tumour, treatment and follow-up data
Characteristic All patients Prostate bed only Prostate bed and pelvis p-value
Number of patients 208 102 106 na
Median age at surgery (range) (years) 65 (49–78) 65 (51–78) 65 (49–78) 0.84
Concomitant disorders 188 92 96
0.95
Diabetes mellitus 27 14 13
Cardiomyopathy 19 11 8
Arterial hypertension 72 32 40
Peripheral vasculopathy 8 3 5
Colon diverticulosis 20 9 11
Dyslipidaemia including hypercholesterolemia 26 14 12
Prior abdominal surgery 26 13 13
Type of surgery
Open 121 61 60
0.75
Robot-assisted laparoscopic approach 87 41 46
Extent of surgery
Prostatectomy 55 18 37
,0.01
Pelvic lymph node dissection1prostatectomy 153 84 69
iPSA, median (range) (ng/ml) 8.28 (0.02–346) 8.6 (0.02–346) 7.4 (0.48–67) 0.4
PSA at the beginning of RT, median (range) (ng/ml) 0.18 (0–18.1) 0.13 (0–18.1) 0.19 (0–8.6) 0.35
Tumour stage after surgerya
pT2 66 38 28
0.14
pT3a 77 38 37
pT3b 59 21 38
pT3c 1 0 1
pT4 4 2 2
Missing 1 1 –
pN0 101 81 20
,0.0001
pN1 34 0 34
pNx 71 20 51
Missing 2 1 1
cM0 107 102 105
0.38
M1 1 – 1
Gleason score after surgery, median (range) 7 (5–10) 7 (5–10) 7 (5–10) 0.97
Margin status
R0 81 43 38
0.1
R1 109 47 62
R0/R1 1 – 1
Missing/na 17 12 5
Time interval surgery—RT, median
(range) (months)
4.5 (1.7–217.3) 4.8 (1.7–217.3) 4.4 (2.1–168.8) 0.22
ADT added to RT
No 130 77 53
,0.001
Yesb 78 25 53
(Continued)
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Table 1. (Continued)
Characteristic All patients Prostate bed only Prostate bed and pelvis p-value
RT intent
Adjuvant 113 53 60
0.28
Salvage (detectable PSA) 95 49 46
RT dose (Gy)
Tumour bed, median (range) 67.1 (45–69) 68.2 (45–69) 66.3 (54–69) 0.47
Pelvis
Positive lymph node areas, median (range) 54 (51–56.1) – 54 (51–56.1) na
Negative lymph node areas, median (range) 51 (45–61) – 51 (45–61) na
Overall RT duration, median (range) (days) 44 (32–67) 44 (37–67) 44 (32–59) 0.70
RT interruption 3 2 1 1
Acute RT toxicityc
Gastrointestinal (bowel)
Grade 0 107 59 48
0.23
Grade 1 75 31 44
Grade 2 25 12 13
Grade 3 1 0 1
Genitourinary
Grade 0 131 68 63
0.39
Grade 1 52 23 29
Grade 2 21 8 13
Grade 3 4 3 1
Follow-upd median (range) (months) 27 (9–47) 27 (9–47) 27 (11–46) 0.33
Late RT toxicityc (evaluated in 206 patients with
follow-up less than 3 months)
206 100 106 –
Gastrointestinal (bowel)
Grade 0 154 77 77
0.89
Grade 1 28 13 15
Grade 2 11 4 7
Grade 3 10 5 5
Grade 4 3 1 2
Genitourinary
Grade 0 120 63 57
0.66
Grade 1 55 22 33
Grade 2 17 8 9
Grade 3 12 6 6
Grade 4 2 1 1
ADT, androgen deprivation therapy; iPSA, initial PSA; na, not available; PSA, prostate-specific antigen; RT, radiotherapy.
In case of ADT concomitant to RT, pre-ADT PSA was registered.
p-value was calculated with x2 test for categorical data and with t-test (two tails) for numeric data.
aAccording to TNM 2009.
bLuteinizing hormone-releasing hormone agonist alone or combined with bicalutamide.
cAccording to the Radiation Therapy Oncology Group/European Organization for Research and Treatment of Cancer criteria.23
dCalculated from the last day of RT to the last contact.
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Clinical and dosimetric potential predictive factors
For each patient, clinical and dosimetric data were collected.
Bowel toxicity and its potential correlation with dosimetric
parameters was investigated. For each patient, DVHs of the
peritoneal cavity and rectum were obtained and analyzed.
Normal tissue complication probability (NTCP) was calculated
from the rectum DVH, based on the Lyman–Kutcher–Burman
model. Late toxicity $ G2 was chosen as the end point.
Radiobiological parameters published by Michalski et al21
were used (n5 0.09; m5 0.13; TD505 76.9Gy, where n describes
the volume effect, m describes the curve steepness and TD50 is the
dose for 50% complication probability). The correlation between
single points of DVH and NTCP was previously analyzed by our
group.22 Analysis was performed in MATLAB® environment
(MATLAB and Statistics Toolbox Release 2008a, MathWorks, Inc.,
Natick, MA).
Statistical analysis
RTOG/European Organization for Research and Treatment of
Cancer criteria were used to evaluate clinically acute and late
treatment toxicity.23 Sexual dysfunction was not analyzed. Late
toxicity was evaluated in patients with follow-up longer than
3 months.
Acute and late bowel and urinary toxicity were compared in the
two groups (PB or P) with x2 test. Stratiﬁcation of the clinical
Table 2. Evaluation of late toxicity at first, second and third year of follow-up
Late RT toxicity Grade TOT Pelvis and prostate bed Prostate bed only x2 test
First year
GI
0 148 81 66
p-value5 0.59
1 21 11 10
2 9 3 6
3 7 4 3
4 1 1 0
GU
0 122 63 59
p-value5 0.47
1 45 28 16
2 16 8 8
3 3 1 2
4 0 0 0
Second year
GI
0 107 64 43
p-value5 0.07
1 21 8 10
2 9 6 1
3 7 2 6
4 1 2 0
GU
0 92 50 42
p-value5 0.28
1 45 21 8
2 16 7 5
3 3 3 5
4 0 1 0
Third year
GI
0 55 24 30
p-value5 0.66
1 6 3 3
2 1 1 0
3 2 1 1
4 1 1 0
GU
0 49 20 29
p-value5 0.08
1 7 6 1
2 2 2 0
3 5 2 3
4 1 0 1
GI, gastrointestinal; GU, genitourinary; RT, radiotherapy; TOT, total number of patients.
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Table 3. Correlation between comorbidities and toxicity. Prior abdominal surgery is correlated with worse acute bowel toxicity
Factor Toxicity Characteristic G0 G1 G2 G3 G4 p-value
Prior abdominal surgery
Acute GI
Yes 12 6 8 0 0
0.02
No 95 69 17 1 0
Acute GU
Yes 17 6 3 0 0
0.87
No 107 42 13 3 0
Late GI
Yes 19 4 0 3 0
0.39
No 135 24 11 7 3
Late GU
Yes 20 5 1 0 0
0.27
No 100 50 16 11 3
Bowel diverticulosis
Acute GI
Yes 11 5 4 0 0
0.56
No 96 70 21 1 0
Acute GU
Yes 13 4 3 0 0
0.76
No 118 48 18 4 0
Late GI
Yes 15 2 0 2 1
0.34
No 139 26 11 8 2
Late GU
Yes 14 5 0 1 0
0.61
No 106 50 17 10 3
Diabetes mellitus
Acute GI
Yes 16 7 4 0 0
0.66
No 91 68 21 1 0
Acute GU
Yes 15 6 6 0 0
0.14
No 116 46 15 4 0
Late GI
Yes 21 4 0 1 1
0.58
No 133 24 11 9 2
Late GU
Yes 14 8 3 1 1
0.76
No 106 47 14 10 2
High blood cholesterol
Acute GI
Yes 26 11 6 0 0
0.40
No 81 64 19 1 0
Acute GU
Yes 25 13 3 2 0
0.22
No 107 42 13 3 0
Late GI
Yes 33 4 4 1 0
0.42
No 121 24 7 9 3
Late GU
Yes 16 6 3 1 0
0.88
No 95 42 14 9 3
Cardiac disorders
Acute GI
Yes 11 6 2 0 0
0.94
No 96 69 23 1 0
Acute GU
Yes 13 4 2 0 0
0.89
No 118 48 19 4 0
Late GI
Yes 13 1 1 3 1
0.08
No 141 27 10 7 2
Late GU
Yes 14 2 2 1 0
0.50
No 106 53 15 10 3
(Continued)
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variables among the two groups was investigated with x2 test for
categorical data and t-test for numeric data. The correlation be-
tween related clinical variables and toxicity was investigated with
x2 test. Concomitant disorders [diverticulosis, diabetes mellitus,
cardiac disorders, high blood pressure, high cholesterol level,
peripheral vasculopathy, prior abdominal surgery other than
prostatectomy and androgen deprivation therapy (ADT) with
bicalutamide or luteinizing hormone-releasing hormone analo-
gous or a combination of both] and correlation between age and
toxicity were investigated with linear correlation coefﬁcient.
The correlation between treatment-related variables and toxicity
was investigated with x2 test for categorical data and with linear
correlation coefﬁcient, Spearman’s r and Kendall’s t rank corre-
lation coefﬁcients for quantitative data. Intent of radiotherapy
(salvage vs adjuvant), type of surgery (open vs robotic vs lapa-
roscopic), extent of surgery (prostatectomy vs prostatectomy and
lymph node dissection), the interval between surgery and radio-
therapy and radiotherapy duration were also investigated.
Table 3. (Continued)
Factor Toxicity Characteristic G0 G1 G2 G3 G4 p-value
High blood pressure
Acute GI
Yes 40 24 7 1 0
0.94
No 67 51 18 0 0
Acute GU
Yes 14 3 3 0 0
0.57
No 117 49 18 4 0
Late GI
Yes 55 8 2 6 0
0.86
No 99 20 9 4 3
Late GU
Yes 45 19 5 2 0
0.47
No 75 36 12 9 3
Peripheral vasculopathy
Acute GI
Yes 3 3 2 0 0
0.68
No 104 72 23 1 0
Acute GU
Yes 5 2 1 0 0
0.98
No 126 50 20 4 0
Late GI
Yes 5 2 1 0 0
0.68
No 149 26 10 10 3
Late GU
Yes 5 1 2 0 0
0.40
No 115 54 15 11 3
Androgen deprivation therapy
Acute GI
Yes 31 22 7 0 0
0.94
No 76 53 18 1 0
Acute GU
Yes 35 18 6 1 0
0.76
No 96 34 15 3 0
Late GI
Yes 49 5 3 2 0
0.42
No 105 23 8 8 3
Late GU
Yes 41 13 4 1 0
0.20
No 79 42 13 10 3
GI, gastrointestinal; GU, genitourinary.
Table 4. Correlation between patient age and toxicity
Factor Toxicity Correlation coefficient r p-value
Patient age
Acute GI 0.02 0.73
Acute GU 0.06 0.41
Late GI 0.1 0.17
Late GU 20.09 0.19
GI, gastrointestinal; GU, genitourinary.
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The systematic analysis of DVH parameters was performed
with Fisher’s exact test. The correlation between volume (in
cubic centimetre) receiving XGy and toxicity was investigated.
Doses were varied between 1 and 70 Gy (with steps of 1 Gy),
volume thresholds were varied between 1 and 3000 cm3 for
the peritoneum (with steps of 1 cm3) and between 1 and
100% for the rectum (with steps of 1%). Acute and late
toxicities with a cut-off at grade G. 0, 1 and 2 were exam-
ined. This is a simple and novel approach that allows exam-
ining a large amount of data in an automated way. Six
matrices of p-values were generated for the rectum DVH and
six for the peritoneum DVH. Each matrix represents a dif-
ferent toxicity threshold (G1, G2 or G3) for acute and late
toxicity. DVH regions of potential interest, where p-values
were ,0.05, were identiﬁed. A tentative DVH constraint was




Between February 2010 and April 2012, 208 patients with
prostate cancer were treated with post-prostatectomy IG-IMRT
at the Division of Radiotherapy of the IEO (Table 1). The PB
and P were treated in 102 and 106 patients, respectively. The two
groups (PB and P) were well balanced with regard to age,
concomitant disorders, type of surgery (open vs robotic or
laparoscopic), tumour stage (T), Gleason score and margin
status, intent of radiotherapy (adjuvant vs salvage), interval be-
tween surgery and radiotherapy, radiotherapy dose and duration
(Table 1). The two groups were not balanced regarding the
Table 5. Correlation between treatment characteristics and toxicity
Factor Toxicity Characteristic G0 G1 G2 G3 G4 p-value
Type of surgery
Acute GI
Laparotomy 59 50 12 0 0
0.38Laparoscopy 4 4 1 0 0
Robotic 44 21 12 1 0
Acute GU
Laparotomy 84 25 11 1 0
0.29Laparoscopy 6 2 1 0 0
Robotic 41 25 9 3 0
Late GI
Laparotomy 85 18 8 6 2
0.07Laparoscopy 4 3 2 0 0
Robotic 65 7 1 4 1
Late GU
Laparotomy 67 36 6 10 1
0.14Laparoscopy 5 2 2 0 0
Robotic 48 17 9 1 2
Lymph node dissection
Acute GI
Yes 81 55 17 0 0
0.25
No 26 20 8 1 0
Acute GU
Yes 97 37 15 4 0
0.83
No 34 15 6 0 0
Late GI
Yes 116 17 8 7 3
0.44
No 38 11 3 3 0
Late GU
Yes 88 39 13 9 3
0.39
No 32 16 4 2 0
Intent of RT
Acute GI
Adjuvant 59 43 10 1 0
0.36
Salvage 48 32 15 0 0
Acute GU
Adjuvant 76 22 12 3 0
0.21
Salvage 55 30 9 1 0
Late GI
Adjuvant 81 19 5 4 2
0.46
Salvage 73 9 6 6 1
Late GU
Adjuvant 63 29 11 7 1
0.76
Salvage 57 26 6 4 2
GI, gastrointestinal; GU, genitourinary; RT, radiotherapy.
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extent of surgery, lymph node staging (pN) and concomitant
ADT. This ﬁnding is indeed expected, as patients with evidence
of lymph node involvement were more likely to receive lymph
node dissection, to be staged as pN1 and to receive pelvic irra-
diation and ADT.
Radiotherapy toxicity
Radiotherapy was well tolerated. All but three patients completed
IG-IMRT. Median follow-up was 27 months (range 9–47 months).
Two patients were lost at follow-up (they have follow-up longer
than 3 months). Late toxicity was evaluated in 206 patients
with follow-up longer than 3 months. Both acute and late
toxicities were limited. No G4 acute events were observed.
Five G4 late events were reported (three urinary events: two
acute urine retention and one haematuria; two bowel events: one
enterovesical ﬁstula requiring temporary colostomy and one in-
testinal bleeding from angiodysplasia treated with argon plasma
coagulation complicated by post-argon plasma coagulation bowel
perforation). No statistical difference in toxicity between Groups PB
and P was found with p-values as follows: acute bowel toxicity with
p-value50.23, late bowel toxicity with p-value5 0.89, acute uri-
nary toxicity with p-value50.39 and late urinary toxicity with
p-value50.66.
A vast majority of patients never reported any toxicity at all
during follow-up [74% always had G0 gastrointestinal (GI)
toxicity and 58% always had G0 genitourinary (GU) toxicity].
Among those who did report some toxicity, the most common
pattern was a stable toxicity level G1–G2 with, in rare cases,
episodes of higher grade toxicity. In this series, there was no
patient with progressive worsening toxicity or with permanent
G3–G4 toxicity. A minority of patients (15% for GI and 27% for
GU) had isolated episodes of G1–G2 toxicity that lasted less than
6 months and resolved completely.
We analyzed the two groups (PB and P), trying to assess late
toxicity evolution over time and focusing on toxicity at 1, 2 and
3 years; the difference was not signiﬁcant at any point in time.
Results are summarized in Table 2. For the rest of the analysis,
we considered late toxicity as the higher reported toxicity during
follow-up.
The correlation between clinical variables and toxicity is shown
in Tables 3 and 4. A statistically signiﬁcant (p-value5 0.02)
correlation between prior abdominal surgery (other than pros-
tatectomy) and acute bowel toxicity was found; interestingly,
there was no correlation between previous surgery and late
bowel toxicity. No other correlation between clinical variables
and toxicity was found. The correlation between treatment-
related parameters and toxicity is shown in Tables 5–7. The only
correlation found was the one between intent of radiotherapy
and GU toxicity, with patients treated post-operatively showing
worse acute and late GU toxicity than those treated at time
of recurrence. There was a strong correlation (p-value,0.01) be-
tween acute and late bowel toxicity, whereas no correlation was
found for urinary toxicity.
Table 6. Correlation between treatment characteristics and toxicity
Factor Toxicity Correlation coefficient r p-value
Interval between surgery and RT
Acute GI 20.05 0.51
Acute GU 20.04 0.59
Late GI 0.09 0.19
Late GU 20.03 0.65
RT duration
Acute GI 0.08 0.26
Acute GU 0.0 0.90
Late GI 0.03 0.67
Late GU 0.08 0.26
GI, gastrointestinal; GU, genitourinary; RT, radiotherapy.
Table 7. Correlation between acute and late toxicity. Acute bowel toxicity was predictive of late bowel toxicity
Correlation Statistics Value p-value
Acute vs late GI toxicity
Correlation coefﬁcient r 0.19 0.005
Spearman’s r 0.3 ,0.0001
Kendall’s t 0.27 ,0.0001
Acute vs late GU toxicity
Correlation coefﬁcient r 20.04 0.005
Spearman’s r 20.02 0.73
Kendall’s t 20.02 0.67
GI, gastrointestinal; GU, genitourinary.
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Dosimetric predictors
Late G2 bowel NTCP varied between 0 and 7.3%. The mean and
standard deviation (SD) of NTCP were 2.0% and 1.3% in the PB
group and 2.3% and 1.3% in the P group. The difference was not
statistically signiﬁcant (Welch’s test p-value5 0.06). As expected,
a signiﬁcant correlation was found between NTCP and late bowel
toxicity. Patients developing late bowel toxicity ,G2 had a mean
NTCP of 2.1% with SD of 1.3%, whereas patients with late bowel
toxicity$G2 had a mean NTCP of 2.7% with SD of 1.0% (Welch’s
test p-value5 0.04). This correlation is shown in Figure 1.
No single peritoneal cavity DVH point was correlated with
probability of developing acute or late bowel toxicity.
Rectal DVH was correlated with bowel toxicity. The portion of
rectum DVH between 32 and 51Gy was strongly (p-val-
ue, 0.01) correlated with acute bowel toxicity G$ 1 (a curve
between 51Gy to 20% of the volume and 32Gy to 53% of the
volume was identiﬁed). Moreover, the portion of rectum DVH
between 48 and 68Gy was strongly (p-value, 0.01) correlated
with late bowel toxicity G$ 2 (a curve between 68Gy to 4% of
the volume and 48Gy to 27% of the volume was identiﬁed).
These potential DVH constraints are shown in Figure 2. In
multivariate analysis, using a logistic model, none of the varia-
bles selected (NTCP and rectum DVH centred around 58Gy for
late GI toxicity and previous surgery and rectum DVH centred
around 42Gy for acute toxicity) retained signiﬁcance.
DISCUSSION
Our study including the clinical and dosimetric data of
208 patients treated with post-prostatectomy IG-IMRT showed
no increase in toxicity in patients treated to the whole pelvis
compared with those irradiated only on the PB. Toxicity in both
groups was low. Our ﬁndings suggest that IG-IMRT allows safe
post-operative irradiation of large volumes.
To the best of our knowledge, this is one of the ﬁrst studies
comparing the toxicity of radiotherapy to the pelvis vs PB only
in the era of high technology.24,25 There are several reports re-
garding pelvic irradiation in the radical setting with an intact
prostate26–28 or comparing pelvic IMRTwith pelvic 3DCRT.29–32
In radical series, the majority of the retrospective analyses
showed some increase in acute toxicity (principally GI rather
than GU) with pelvic radiotherapy.26,33 Some studies, however,
did not show any statistically signiﬁcant increase in toxicity in
patients treated to the pelvis.26,34–36 In a recent study from
Norway, males treated for high-risk or locally advanced prostate
cancer with IMRT including the prostate and pelvis had more
acute side effects at 3 months than those treated with 3DCRT to
the prostate only.28 Interestingly, at 12-month follow-up, the
observed urinary and bowel function and bother were similar in
both groups. In the post-prostatectomy setting, Van Praet et al24
compared pelvic IMRT (48 patients) with PB only (239 patients)
in a matched case analysis. The differences between the groups
were similar to those observed in our study (ADT, N-stage etc.).
Pelvic volumes were bigger than those in our study; the presacral
lymph node area was included (increasing the dose to organs at
risk). This difference may at least partially explain the results of
Van Praet et al’s study:24 acute and late lower intestinal toxicity
was signiﬁcantly higher following pelvic IMRT (acute G2 tox-
icity is 42% in whole pelvis vs 15% in PB-only irradiation; late
G2 toxicity is 30% in the whole pelvis vs 15% in PB-only
Figure 2. The dose–volume histogram (DVH) constraint for
acute bowel [gastrointestinal (GI)] toxicity$G1 (solid black
line) and the DVH constraint for late GI toxicity$G2 (dotted
grey line) are shown. Gy, gray.
Figure 1. (a) The regression line of normal tissue complication probability (NTCP) to the measured toxicity is shown. As can be
observed, data are rather sparse. The R correlation coefficient is 0.134 (95% confidence interval: 20.03 to 0.266). (b) NTCP
distribution in patients developing late bowel [gastrointestinal (GI)] toxicity of increasing grade is shown.
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irradiation), while acute and late urinary toxicity was similar in
both groups (acute toxicity G$ 2 is 40% in whole pelvis vs 29%
in PB-only irradiation; late toxicity G$ 2 is 50% in whole pelvis
vs 35% in PB-only irradiation). Deville et al25 in their retro-
spective study on 67 patients found a signiﬁcant increase only in
acute bowel toxicity (61% vs 29% G$ 2 toxicity in whole pelvis
irradiation and PB-only irradiation, respectively), and no dif-
ference in late bowel toxicity (3% vs 0%) or acute (22% vs 7%)
and late (17% vs 13%) urinary events, when pelvic IMRT was
compared with PB-only IMRT. As in our study, the presacral
area was not included. In a multi-institutional retrospective
analysis of 959 patients, adjuvant radiotherapy, ADT and PB-
only radiotherapy were statistically signiﬁcantly predictive for
G2 (or higher) late GU toxicity.37
We are well aware of the limitations of our study, including its
retrospective character and the length of median follow-up. A
retrospective study carries the risk of selection bias (decision
between PB vs pelvic irradiation) and may suffer from missing
data and lack of baseline and regular follow-up information. An
inadequate follow-up length may result in missing tardive events
such as, for this kind of therapy, late GU toxicity that may
appear even 5–8 years after the end of treatment. Indeed, some
studies reported late rectal toxicity of 11% and urinary toxicity
of 16% after a median follow-up of 70 months38 or 5-year
freedom from late rectal and urinary toxicity ($G2) rates of
95% and 88%, respectively.39 However, few data are available
about longer toxicity follow-up after whole pelvic IMRT, thus
prompting the need for further studies to better characterize
these very late toxicities and help physicians prevent and manage
them.40 However, in our study, the two groups were well bal-
anced, apart from the known factors correlated with indication
for pelvic irradiation (pelvic lymph node dissection showing
positive lymph nodes). All the procedures including indications
for radiotherapy volume, radiotherapy simulation, planning and
delivery and patient monitoring are well standardized in our
institution. The post-treatment follow-up radiotherapy or
urology appointments are scheduled with 6–9-month intervals,
which could lead to underevaluation of late toxicity; however,
the patients are instructed to inform the clinician about any
clinically signiﬁcant event in the interval between appointments.
Therefore, we do believe that our study may represent a solid
basis for further investigation on the impact of volume in the era
of high-precision prostate cancer radiotherapy.
Our data conﬁrm the utility of NTCP with the Lyman–
Kutcher–Burman model. Most treatment planning systems do not
optimize biological parameters, but require DVH constraints. Our
data-mining approach could detect the potentially signiﬁcant
DVH region. These data suggest that low-grade acute toxicity is
mainly due to medium doses delivered to a large volume of the
rectum, whereas higher grade late toxicity is mainly due to high
doses delivered to a small volume of the rectum. Data mining
without an underlying physiopathological model has to be con-
sidered as “hypothesis generating”, and these ﬁndings need to be
conﬁrmed prospectively. Only rectal DVH was correlated with
bowel toxicity. The peritoneal cavity was delineated instead of
single bowel loops, as this method was considered safer against
bowel movement. It is relevant to acknowledge that a better in-
vestigation of the dose–response relationship for the small bowel
would demand an evaluation of accumulated dose as achievable
with daily volumetric imaging and reliable deformable regis-
tration. However, this information was not available for this
study. Therefore, the peritoneal cavity DVH was selected as
a more reliable surrogate with respect to bowel loop DVH, as
the latter could be strongly inﬂuenced by the position of the
bowel loop in the planning CT scan. For the same reason, we
did not investigate the correlation between inhomogeneous
spatial distributions of dose and the aetiopathogenesis of
radiation-induced GI toxicity.41
No point in the peritoneal cavity DVH correlated signiﬁcantly
with GI toxicity. This of course does not mean that dose to the
peritoneal cavity is not toxic but rather that the IMRT technique
employed and the dose constraint used allowed the treatment of
pelvic lymph nodes without exceeding the threshold of clinically
detectable toxicity. Correlation between previous abdominal
surgery and bowel toxicity is well known in prostate and
gynaecological radiotherapy.42,43 It is, however, interesting to
point out that the group with previous surgery had an increase
of G1–G2 scores, but not of G3 toxicity. Correlation between
acute and late toxicity was also expected.44,45 Genetic features
are involved in toxicity; however, this aspect was not investigated
in our series.46,47
The fact that the signiﬁcance of DVH parameter, NTCP and
previous surgery was not conﬁrmed in multivariate analysis is
probably owing to the underlying assumption of logistic mul-
tivariate regression, whereas more general models could be used
in univariate analysis.
In conclusion, our study has not demonstrated any increase in
acute or late bowel or urinary toxicity when IG-IMRT was ad-
ministered to the pelvic lymph node area when compared with
IG-IMRT to the prostate bed only. Further investigation is
warranted to exclude bias due to non-randomized character of
the study.
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